Invivyd upsizes COVID-19 trial, targets measles antibody

Biotechnology firm Invivyd, based in Waltham, Massachusetts, announced on Monday that it has expanded the enrollment target for its Phase 2/3 clinical trial of its COVID-19 monoclonal antibody candidate, VYD222. The company is strategically pivoting its resources, simultaneously revealing a new research initiative to develop a long-acting antibody for measles prevention, a move driven by the evolving pandemic landscape and shifting commercial opportunities in the COVID-19 therapeutic market. The decision to upsize the COVID-19 trial, named CANOPY, reflects a targeted approach to gather more robust data on VYD222's efficacy in immunocompromised patients, a high-risk population. This expansion is designed to strengthen the potential regulatory submission package for the antibody, which is engineered to neutralize current circulating variants. Concurrently, the launch of the measles antibody program represents a significant strategic diversification for Invivyd, aiming to address a critical global health need where vaccine coverage gaps persist and outbreaks have resurged in various regions. This dual announcement underscores a broader trend in the biotech sector, where companies are adapting their pipelines in response to market dynamics. For Invivyd, the COVID-19 antibody space has become increasingly competitive and commercially uncertain, prompting a reallocation of R&D efforts toward areas with clearer unmet medical needs and long-term viability. The measles initiative leverages the company's core antibody platform technology in a new disease area, potentially opening future revenue streams while contributing to public health preparedness.